Healthcare

Restoring Community Oversight of Sober Living Homes Act of 2018

United States · United States Congress · 9 May 2018

Restoring Community Oversight of Sober Living Homes Act of 2018 This bill amends the Patient Protection and Affordable Care Act to remove substance use disorder services from the list of essential health benefits that must be covered by health plans. The bill also amends the Fair Housing Act to address state and local zoning laws regarding recovery facilities (buildings that are occupied by individuals who are handicapped by drug addiction or alcoholism and that prohibit controlled substances and alcohol). The bill specifies that federal anti-discrimination laws do not bar any state or local zoning laws that prohibit recovery facilities in residential areas. Recovery facilities must also comply with all state and local zoning laws in order to receive federal funds.

Expressing support for the designation of May 2018 as "Mental Health Month".

United States · United States Congress · 9 May 2018

Supports the designation of Mental Health Month to remove the stigma associated with mental illness and to place emphasis on scientific findings regarding mental health recovery.

HOST Act of 2018

United States · United States Congress · 8 May 2018

Hospital Opioid Solutions Toolkit Act of 2018 or the HOST Act of 2018 This bill requires the Centers for Medicare & Medicaid Services to publish guidance for hospitals on pain management and opioid-use disorder prevention strategies for Medicare beneficiaries, including best practices for opioid-use disorder screening, education, and monitoring.

Medicaid Drug Rebate Accountability Act

United States · United States Congress · 8 May 2018

Medicaid Drug Rebate Accountability Act This bill requires drug manufacturers with Medicaid rebate agreements for covered outpatient drugs to correct any misclassifications of such drugs within a specified time period, and establishes civil penalties for failures to do so.

Improving Access to Mental Health Services Act

United States · United States Congress · 8 May 2018

Improving Access to Mental Health Services Act This bill amends the Public Health Service Act to allow National Health Service Corps (NHSC) personnel who are assigned to provide health services in a health professional shortage area to provide services as behavioral and mental health professionals at schools or other community-based settings and at the homes of patients. Services provided pursuant to this bill may count toward completion of obligated service requirements under the NHSC scholarship or loan repayment programs.

Preventing NAS and Protecting Babies Act

United States · United States Congress · 8 May 2018

Preventing NAS and Protecting Babies Act This bill requires the Department of Health and Human Services to develop a strategy for implementing recommendations from a departmental report on prenatal opioid exposure and neonatal abstinence syndrome (a syndrome in which newborns exhibit withdrawal symptoms because of substance use during pregnancy). The strategy must include timelines for implementation, resources for state health agencies, and recommendations for any needed statutory changes.

SOUND Disposal and Packaging Act

United States · United States Congress · 7 May 2018

Securing Opioids and Unused Narcotics with Deliberate Disposal and Packaging Act of 2018 or the SOUND Disposal and Packaging Act This bill amends the Federal Food, Drug, and Cosmetic Act to authorize the Food and Drug Administration to require certain packaging and disposal technologies, controls, or measures to mitigate the risk of abuse or misuse of a drug or a class of drugs.

Medicare Opioid Safety Education Act of 2018

United States · United States Congress · 7 May 2018

Medicare Opioid Safety Education Act of 2018 This bill requires the Centers for Medicare & Medicaid Services to provide Medicare beneficiaries with educational resources regarding opioid use and pain management, as well as descriptions of covered alternative (non-opioid) pain-management treatments.

Medicare CHOICE Act of 2018

United States · United States Congress · 7 May 2018

Medicare Clear Health Options in Care for Enrollees Act of 2018 or the Medicare CHOICE Act of 2018 This bill requires Medicare and Medicare Advantage prescription drug plan (PDP) sponsors to annually disclose information to enrollees about: (1) the adverse effects of prolonged opioid use; and (2) the plan's coverage of nonpharmacological therapies, devices, and non-opioid medications. PDP sponsors may limit disclosure to a subset of enrollees (such as those who were prescribed an opioid in the previous two-year period).

Protecting Seniors From Opioid Abuse Act

United States · United States Congress · 7 May 2018

Protecting Seniors From Opioid Abuse Act This bill establishes individuals who are identified as at-risk beneficiaries for prescription drug abuse as qualifying participants in medication therapy management programs under the Medicare prescription drug benefit.

REMC Act of 2018

United States · United States Congress · 7 May 2018

Rural Emergency Medical Center Act of 2018 or the REMC Act of 2018 This bill establishes several requirements under Medicare regarding certified rural emergency medical centers, including payment, certification, and participation requirements.

Emmett's Law

United States · United States Congress · 7 May 2018

Emmett's Law This bill requires the Centers for Medicare & Medicaid Services and the Health Resources and Services Administration to notify annually health care providers about health information that may be disclosed under federal privacy laws to families, caregivers, and health care providers during emergencies, including overdoses. The notification may be included in other (already required) training materials for health care providers relating to permitted disclosures of patients' mental or substance use disorder treatment information.

Department of Veterans Affairs Oversight Enhancement Act of 2018

United States · United States Congress · 7 May 2018

Department of Veterans Affairs Oversight Enhancement Act of 2018 This bill requires the Department of Veterans Affairs (VA) to report on its corrective measures any year health care furnished by the VA appears on the high risk list published by the Government Accountability Office (GAO). The high risk list is a list of programs that are vulnerable to fraud, waste, abuse, and mismanagement or that need transformation. The VA is also required to report annually on the implementation of recommendations from GAO.

VA Medicinal Cannabis Research Act of 2018

United States · United States Congress · 7 May 2018

VA Medicinal Cannabis Research Act of 2018 This bill authorizes the Department of Veterans Affairs (VA) to conduct and support research on the efficacy and safety of certain forms of cannabis and cannabis delivery for veterans enrolled in the VA health care system diagnosed with conditions such as chronic pain or post-traumatic stress disorder. Collected data shall be preserved in a manner that facilitates further research.

SENIOR Communities Protection Act of 2018

United States · United States Congress · 3 May 2018

Stop Excessive Narcotics in our Retirement Communities Protection Act or the SENIOR Communities Protection Act This bill authorizes the suspension of payments to a pharmacy under the Medicare prescription drug benefit and Medicare Advantage prescription drug plans pending the investigation of a credible allegation of fraud by the pharmacy. A fraud hotline tip, without other evidence, may not be considered a credible allegation of fraud.

To amend title XVIII of the Social Security Act to require prescription drug plan sponsors under the Medicare program to establish drug management programs for at-risk beneficiaries.

United States · United States Congress · 3 May 2018

This bill requires Medicare prescription drug plan (PDP) sponsors, for plan years beginning on or after January 1, 2021, to establish drug management programs for at-risk beneficiaries. Current law authorizes, but does not require, PDP sponsors to establish such programs.

VA MISSION Act of 2018

United States · United States Congress · 3 May 2018

VA Maintaining Internal Systems and Strengthening Integrated Outside Networks Act of 2018 or VA MISSION Act of 2018 This bill consolidates Department of Veterans Affairs (VA) community care programs, revises other VA health care programs and facilities provisions, and makes appropriations for veterans care. The bill establishes the Veterans Community Care Program to furnish hospital care, medical services, and extended care services through certain non-VA providers to veterans who are enrolled in the VA health care system or otherwise entitled to VA care. The VA may enter agreements with non-VA providers to furnish veterans with care that is otherwise not feasibly available. The VA shall: (1) establish standards for VA health care quality and for non-VA care in areas of VA expertise, (2) prohibit rehiring previously-removed VA providers, (3) provide prompt payment to providers, (4) establish opioid prescribing practices for non-VA providers, and (5) carry out the modernization or realignment of Veterans Health Administration facilities. The Veterans Choice Program is terminated after one year. The bill establishes: (1) the Center for Innovation for Care and Payment, and (2) the Asset and Infrastructure Review Commission. The VA may: (1) provide care for the live donor of a transplant for a veteran, and (2) carry out a Specialty Education Loan Repayment Program and other actions to recruit health care professionals. The VA family caregiver program is expanded. The Office of Management and Budget shall review each enhanced-use facility lease. The bill establishes pilot programs for medical scribes, mobile deployment teams for underserved facilities, and graduate medical education. The bill extends VA pension reductions for Medicare-covered veterans in nursing homes.

POPPY Study Act

United States · United States Congress · 27 April 2018

Protecting against Opioid Prescription-abuse during Prenatal Year Study Act or the POPPY Study Act This bill requires the Department of Health and Human Services to submit a report to Congress that includes details regarding: opioid prescribing practices for pregnant women, recommendations for identifying and reducing opioid misuse during pregnancy, prescription opioid use and misuse during pregnancy in urban and rural areas, the use of non-opioid pain management practices in place of prescription opioids during pregnancy, guidelines encouraging the use of non-opioid pain management practices during pregnancy when safe and effective, and recommendations for increasing public awareness and education regarding opioid use disorder in pregnancy.

Recognizing the seriousness of Polycystic Ovary Syndrome (PCOS) and expressing support for the designation of the month of September 2018 as "PCOS Awareness Month".

United States · United States Congress · 27 April 2018

Expresses support for the goals and ideals of Polycystic Ovary Syndrome (PCOS) Awareness Month. (PCOS is caused by a hormone imbalance. Symptoms can include infertility, weight gain, excess hair growth, and acne.) Recognizes the need for further research, improved treatment and care options, and a cure for PCOS. Acknowledges the struggles affecting all women and girls afflicted with PCOS.

Identifying Innovative Practices and Technology In Health Care

United States · United States House of Representatives · 26 April 2018

Medical Cannabis Research Act of 2018

United States · United States Congress · 26 April 2018

Medical Cannabis Research Act of 2018 This bill amends the Controlled Substances Act to establish a new, separate registration process for manufacturers of cannabis for research. The Drug Enforcement Administration must assess whether there is an adequate and uninterrupted supply of research cannabis and register additional manufacturers.

Pathway to Universal Coverage Act of 2018

United States · United States Congress · 26 April 2018

Pathway to Universal Coverage Act of 2018 This bill requires the Department of Health and Human Services to award grants to states for the purpose of promoting health insurance enrollment, such as through auto-enrollment programs.

State Offices of Rural Health Reauthorization Act of 2018

United States · United States Congress · 26 April 2018

State Offices of Rural Health Reauthorization Act of 2018 This bill amends the Public Health Service Act to reauthorize through FY2022 and revise the grant program for state offices of rural health, including to require the Department of Health and Human Services (HHS) to make the grants, thus removing HHS's discretion to make them.

Responsible Opioid Prescription Act

United States · United States Congress · 26 April 2018

Responsible Opioid Prescription Act This bill limits Medicaid coverage of opioids prescribed to enrollees other than those who are in long-term care facilities or who are receiving hospice care, palliative care, or treatment for cancer.

Easy Enrollment Act of 2018

United States · United States Congress · 26 April 2018

Easy Enrollment Act of 2018 This bill amends the Patient Protection and Affordable Care Act to shift the annual open enrollment period for health care exchanges. Beginning with calendar 2020, the annual open enrollment period must begin on a date set by the Department of Health and Human Services and must end on April 15 of that calendar year. Under current law, for benefit years beginning on or after January 1, 2018, the annual open enrollment period begins on November 1 and ends on December 15 of the calendar year preceding the benefit year.

A bill to require the Secretary of Health and Human Services to provide for an action plan on recommendations for changes under Medicare and Medicaid to prevent opioids addictions and enhance access to medication-assisted treatment, and for other purposes.

United States · United States Congress · 26 April 2018

This bill requires the Centers for Medicare & Medicaid Services (CMS) to develop an action plan to provide recommendations on changes to the Medicare and Medicaid programs to enhance: (1) the treatment and prevention of opioid addiction, and (2) the coverage and reimbursement of medication-assisted treatment for opioid addiction. The CMS must convene a stakeholder meeting to solicit public comment on the action plan.

Opioid Minority Health Report to Congress Act of 2018

United States · United States Congress · 25 April 2018

Opioid Minority Health Report to Congress Act of 2018 This bill requires the National Institute of Minority Health and Health Disparities to report annually on the impact of the opioid epidemic on racial and ethnic minority groups, including the scope of the epidemic, whether expansion of coverage for medication-assisted treatment under the Medicare and Medicaid programs could decrease opioid use and overdose deaths, and the extent of participation by such groups in pain management clinical trials.

A resolution supporting the designation of April 2018 as "Parkinson's Awareness Month".

United States · United States Congress · 25 April 2018

Designates April 2018 as Parkinson's Awareness Month. Expresses support for research to find better treatments and a cure for Parkinson's disease. Recognizes individuals living with Parkinson's disease who participate in clinical trials. Commends the dedication of organizations, volunteers, researchers, and millions of individuals across the United States working to improve the quality of life for individuals living with Parkinson's disease and their families.

Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act

United States · United States Congress · 24 April 2018

Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act This bill requires the Centers for Medicare & Medicaid Services (CMS) to carry out a demonstration program to: (1) increase access of opioid use disorder treatment services for Medicare beneficiaries, (2) improve physical and mental health outcomes for such beneficiaries, and (3) reduce Medicare expenditures. Opioid use disorder care teams of practitioners may apply for participation in the demonstration project. The CMS must establish a performance-based incentive payment for participating teams. The CMS must adopt or develop program quality standards and performance methods.

Access to Telehealth Services for Substance Use Disorders Act

United States · United States Congress · 24 April 2018

Access to Telehealth Services for Opioid Use Disorders Act This bill authorizes the Centers for Medicare & Medicaid Services to waive certain requirements with respect to payment for telehealth services provided to a Medicare beneficiary who is receiving treatment for an opioid-use disorder or a co-occurring mental-health disorder.

Animal Health and Innovation Act of 2018

United States · United States Congress · 24 April 2018

Animal Health and Innovation Act of 2018 This bill amends the Federal Food, Drug, and Cosmetic Act to expand the authority of the Food and Drug Administration to conditionally approve a new animal drug that (1) is intended to treat a serious or life-threatening disease or condition or address an unmet animal or human health need, and (2) a demonstration of effectiveness would require a complex or particularly difficult study or studies.

340B Optimization Act

United States · United States Congress · 24 April 2018

340B Optimization Act This bill requires federally-qualified health centers, children's hospitals, and other covered entities participating in the 340B drug discount program to report annually on information regarding low-income outpatient utilization rates.

Opioid Addiction Action Plan Act

United States · United States Congress · 24 April 2018

Opioid Addiction Action Plan Act This bill requires the Centers for Medicare & Medicaid Services (CMS) to develop an action plan to provide recommendations on changes to the Medicare and Medicaid programs to enhance: (1) the treatment and prevention of opioid addiction, and (2) the coverage and reimbursement of medication-assisted treatment for opioid addiction. The CMS must convene a stakeholder meeting to solicit public comment on the action plan.

Recognizing Meningitis B Awareness Day.

United States · United States Congress · 24 April 2018

Recognizes Meningitis B Awareness Day. (Meningococcal disease is more commonly referred to as bacterial meningitis and can cause an infection of the lining of the brain and spinal cord.)

RESTRICT Illicit Drugs Act

United States · United States Congress · 24 April 2018

Restricting Entrance and Strengthening the Requirements on Import Controls for Trafficking of Illicit Drugs Act or the RESTRICT Illicit Drugs Act This bill requires the Food and Drug Administration (FDA) to transfer any packages of illegally imported drugs it receives to the U.S. Customs and Border Protection. The FDA may (1) debar a person from importing drugs into the United States if they have been convicted of a drug import related felony, and (2) refuse admission of an article imported by someone who is debarred, except that a counterfeit drug must be refused.

Defending Access to Mental Health Care Act

United States · United States Congress · 24 April 2018

Defending Access to Mental Health Care Act This bill amends the Public Health Service Act to expand the National Health Service Corps Program to include service in pediatric inpatient mental health facilities (such facilities may qualify as health professional shortage areas under the program).

Peer Support Communities of Recovery Act

United States · United States Congress · 23 April 2018

Peer Support Communities of Recovery Act This bill amends the Public Health Service Act to allow the Substance Abuse and Mental Health Services Administration to award grants to nonprofits that focus on substance use disorder to establish regional technical assistance centers to provide assistance regarding implementation of peer-delivered addiction recovery support services, establishment of recovery community organizations and centers, and overdose reversal medication.

To amend title XI of the Social Security Act to require States to annually report on certain adult health quality measures, and for other purposes.

United States · United States Congress · 23 April 2018

This bill requires the Centers for Medicare & Medicaid Services to expand its core set of adult health quality measures for Medicaid-eligible adults to include measures specific to behavioral health. A state Medicaid program must report annually on such measures.

Abuse Deterrent Access Act of 2018

United States · United States Congress · 23 April 2018

Abuse Deterrent Access Act of 2018 This bill requires the Centers for Medicare & Medicaid Services to report to Congress on the adequacy of access to abuse-deterrent opioid formulations for individuals with chronic pain enrolled in a prescription drug plan under Medicare or Medicare Advantage (MA). The report must account for any barriers preventing enrollees from accessing such formulations under Medicare or MA.

STOP Fentanyl Deaths Act of 2018

United States · United States Congress · 23 April 2018

Surveillance and Testing of Opioids to Prevent Fentanyl Deaths Act of 2018 or the STOP Fentanyl Deaths Act of 2018 This bill establishes and expands programs to support increased detection and monitoring of fentanyl and other synthetic opioids, and also establishes a pilot program for point-of-use testing of illicit drugs for dangerous contaminants.

CAREER Act

United States · United States Congress · 23 April 2018

Comprehensive Addiction Recovery through Effective Employment and Reentry Act or the CAREER Act This bill amends the Public Health Service Act to require the Department of Health and Human Services (HHS) to establish a pilot program to award grants to states in order to assist individuals with the transition from substance use disorder treatment programs to independent living and the workforce. Eligible grant activities include outpatient treatment programs, care coordination services, and vocational training. HHS may award five-year grants to up to five states (based in part on specified unemployment and overdose data) and one-year grants to states and Indian tribes (based on criteria determined by HHS). Additionally, the bill amends the Housing and Community Development Act of 1974 to include temporary housing services for individuals transitioning from substance use disorder treatment programs as qualifying activities for which states may use federal funds. The bill also amends the Workforce Innovation and Opportunity Act and the Rehabilitation Act of 1973 to allow states to use federal funds for career and training services for such individuals, including career counseling, employee assistance programs, and educational resources for employers.

Addiction Prevention and Responsible Opioid Practices Act

United States · United States Congress · 23 April 2018

Addiction Prevention and Responsible Opioid Practices Act This bill establishes a series of requirements relating to opioid regulation, prescribing, and monitoring, including licensure requirements for pharmaceutical representatives, a national opioid drug mapping tool to monitor prescribing practices of Medicaid providers, and an excise tax on opioid manufacturers.

Reducing Obesity in Youth Act of 2018

United States · United States Congress · 23 April 2018

Reducing Obesity in Youth Act of 2018 This bill requires the Department of Health and Human Services (HHS), in coordination with the Centers for Disease Control and Prevention and the Administration for Children and Families, to award grants to promote healthy eating and physical activity among children under six years old in early care and education settings. HHS must track the obesity prevention policies and practices of early care and education programs.

A resolution designating April 2018 as "National Donate Life Month".

United States · United States Congress · 23 April 2018

Expresses support for the goals and ideals of National Donate Life Month and for promoting awareness of organ donation.

Protecting Moms and Infants Act

United States · United States Congress · 19 April 2018

Protecting Moms and Infants Act This bill reauthorizes through FY2023 the residential substance-use-treatment program for pregnant and postpartum women and requires the Department of Health and Human Services to make recommendations for addressing prenatal opioid use. Further, the Center for Substance Abuse Treatment must develop substance-use-disorder educational materials for treating pregnant women and babies.

Animal Drug and Animal Generic Drug User Fee Amendments of 2018

United States · United States Congress · 18 April 2018

Animal Drug and Animal Generic Drug User Fee Amendments of 2018 TITLE I--FEES RELATING TO ANIMAL DRUGS This bill addresses the authority of the Food and Drug Administration (FDA) to collect new animal drug (brand name animal drug) and generic animal drug user fees. Animal Drug User Fee Amendments of 2018 (Sec. 103) The bill amends the Federal Food, Drug, and Cosmetic Act to reauthorize through FY2023 the authority of the FDA to collect and use brand name animal drug user fees. The FDA must not collect fees for (1) supplemental applications that are submitted solely to add the animal drug application number to the label of the drug, and (2) applications for genetically engineered animals that are intended to produce human medical products. The bill revises the total amount of revenue brand name animal drug user fees can generate. The bill also revises the requirements for calculating adjustments to revenue amounts based on changes in the workload for reviewing brand name animal drug applications. (Sec. 104) The bill extends requirements for the FDA to report to Congress on achieving goals related to the animal drug development and review processes and implementation of the authority to collect brand name animal drug user fees. (Sec. 107) The bill terminates the authority of the FDA to collect brand name animal drug user fees on October 1, 2023. TITLE II--FEES RELATING TO GENERIC ANIMAL DRUGS Animal Generic Drug User Fee Amendments of 2018 (Sec. 202) The bill reauthorizes through FY2023 the authority of the FDA to collect and use generic animal drug user fees. The FDA must not collect fees for supplemental abbreviated applications that are submitted solely to add the generic animal drug application number to the label of the drug. The bill revises the total amount of revenue each type of generic animal drug user fee must generate. The bill also revises the requirements for calculating adjustments to revenue amounts based on changes in the workload for reviewing generic animal drug applications. (Sec. 203) The bill extends requirements for the FDA to report to Congress on achieving goals related to the generic animal drug development and review process and the implementation of the authority to collect generic animal drug fees. (Sec. 206) The bill terminates the authority of the FDA to collect generic animal drug user fees on October 1, 2023. TITLE III--MISCELLANEOUS PROVISIONS (Sec. 301) Brand name and generic animal drug applications must be submitted electronically beginning in FY2019. Additionally, applications for conditional approval of brand name animal drugs for minor use and minor species must be submitted electronically beginning in FY2019. (Minor use drugs are for intended uses in major species [horses, dogs, cats, cattle, pigs, turkeys, and chickens] for diseases that occur infrequently or in limited geographic areas and in only a small number of animals annually.) (Sec. 302) Product labeling for certain unapproved brand name animal drugs for minor species must include the index number in order to be marketed. (Sec. 303) The bill prohibits the sale of brand name animal drugs that do not include the FDA application number. (Sec. 304) The bill authorizes the FDA to grant conditional approval of a brand name animal drug not intended for a minor use or minor species if (1) the drug is intended to treat a serious or life-threatening disease or condition or addresses an unmet animal or human health need, and (2) the FDA determines that a demonstration of effectiveness of the drug would require a complex or particularly difficult study or studies. The FDA must issue guidance or regulations that provide further details regarding the criteria for conditional approval. The bill terminates this conditional approval authority on October 1, 2028. The Government Accountability Office must study the effects of the conditional approval pathway for brand name animal drugs. (Sec. 305) The FDA must issue guidance on how to evaluate certain elements of investigations as part of the animal drug application process, and how drug sponsors may obtain feedback from the agency on technical issues before submitting an application. (Sec. 306) The FDA must review investigations conducted in foreign countries when acting on a petition for a food additive intended for use in animal food. The FDA must also issue guidance on the voluntary pre-petition consultation process for such food additives.

Comprehensive Addiction Resources Emergency Act of 2018

United States · United States Congress · 18 April 2018

Comprehensive Addiction Resources Emergency Act of 2018 This bill establishes a series of grant programs to assist localities with addressing the opioid epidemic, such as through prevention and treatment services, training centers, and research activities.

Protecting NAS Babies Act

United States · United States Congress · 18 April 2018

Protecting Neonatal Abstinence Syndrome Babies Act or the Protecting NAS Babies Act This bill requires the Department of Health and Human Services to develop a strategy for implementing recommendations from a departmental report on prenatal opioid exposure and neonatal abstinence syndrome (a syndrome in which newborns exhibit withdrawal symptoms because of substance use during pregnancy). The strategy must include timelines for implementation, resources for state health agencies, and recommendations for any needed statutory changes.

Alternatives to Opioids Prescribing Act

United States · United States Congress · 18 April 2018

Alternatives to Opioids Prescribing Act This bill requires the Centers for Medicare & Medicaid Services (CMS) to carry out a demonstration project to evaluate alternatives to the use of opioids to treat Medicare enrollees in hospital emergency departments. Under the project, the CMS must provide incentive payments to participating hospitals for decreasing the use of opioids and increasing the use of opioid alternatives.

To amend the Public Health Service Act to authorize certain grantees to contract with or make subawards to local or regional organizations that are private and nonprofit, and that may be faith-based, and for other purposes.

United States · United States Congress · 18 April 2018

This bill specifies that certain Substance Abuse and Mental Health Services Administration (SAMHSA) programs may award grants, and grantees may make subgrants, to local or regional nonprofit organizations, including faith-based organizations. The bill also specifies that SAMHSA may renew grants to residential treatment programs for pregnant and postpartum women for up to five years.